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Abstract  28 
OBJECTIVE. UV-A/Riboflavin crosslinking of corneal collagen fibers (CXL) is a highly 29 
promising therapy for corneal melting in humans. A prospective interventional, non-30 
randomized, controlled study was conducted to compare the stabilizing effect of CXL 31 
treatment on melting keratitis in dogs and cats and the complication rate of CXL to those of 32 
standardized intensive medical treatment. 33 
PROCEDURES. Forty-nine eyes with melting keratitis were included in the study between 34 
October 2009 and October 2012. All eyes were treated according to the same medical 35 
treatment protocol. Nineteen eyes were CXL-treated and 30 eyes were not. Follow-up 36 
included slit-lamp examination, fluorescein staining, ulcer size measurement, stromal stability 37 
evaluation, photographic documentation and documentation of complications. 38 
RESULTS. Five of 19 eyes in the CXL group and 9/30 eyes in the control group required 39 
rescue stabilization due to continued melting. Seven of the 9 control group corneas stabilized 40 
after rescue CXL treatment. At initial presentation, the ulcers in the canine CXL group were 41 
significantly deeper and larger than in the control group. Ulcer deepening during follow-up 42 
was more pronounced in the canine control group than in the canine CXL group. CXL 43 
treatment related complications were not observed. 44 
CONCLUSIONS. Based on the similar failure rates in the control and CXL treatment groups 45 
despite the poorer initial situation in the CXL group, the tendency for the ulcers in the control 46 
group to deepen and the stabilization of all corneas receiving CXL rescue treatment, we 47 
believe that CXL has its place as an adjunctive therapy for melting keratitis in veterinary 48 
ophthalmology. 49 
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Introduction 53 
Melting keratitis or keratomalacia is a serious condition which occurs with relative frequency 54 
in veterinary ophthalmology, especially in predisposed breeds.(1-4) Melting keratitis is 55 
caused by the release of endogenous and exogenous collagenolytic enzymes and an imbalance 56 
between these proteolytic enzymes and the proteinase inhibitors present in the cornea and 57 
precorneal tear film.(5, 6) Such a release of collagenases can be caused by primary diseases of 58 
the ocular surface that weaken the cornea’s anatomic barriers and physiologic defenses (like 59 
low corneal sensation, quantitative and qualitative tear film deficiencies, exposure keratitis, 60 
trauma, eyelid abnormalities etc.), topical medications, systemic immune mediated diseases 61 
and secondary bacterial or fungal corneal infections.(7-10) 62 
If uncontrolled, melting keratitis can lead to complete structural disintegration of the cornea, 63 
corneal perforation and eventual loss of the eye.(3, 4) Aggressive treatment with topical 64 
antimicrobials to battle a potential infection and with anticollagenases to directly counter 65 
collagenolysis is are therefore indicated to stop progression of the melting process.(5) 66 
Surgical stabilization of the cornea is indicated when significant progression of the melting 67 
process despite medical therapy is observed or when the integrity of the globe is significantly 68 
compromized at initial presentation.(3) Conjunctival grafts are typically used since they 69 
provide tectonic, antimicrobial and anticollagenase support for a melting ulcer. However, the 70 
use of conjunctival grafts exacerbates the corneal opacity which develops as a result of 71 
corneal stromal ulcer healing. Depending on the initial lesion size, depth and localization, the 72 
residual visual impairment can be more or less severe.(3, 11, 12)  Another major problem is 73 
the potential rapid progression of melting keratitis, which makes timely control over the 74 
disease process difficult, both with medical and conventional surgical intervention. 75 
Natural covalent cross-links between the corneal collagen fibers improve the biomechanical 76 
stability of the cornea. Crosslinking of corneal collagen (CXL) uses riboflavin (Vitamin B2) 77 
which acts as a photosensitizer when exposed to UV-A light with a wavelength at the 78 
riboflavin absorption peak of 370nm. This results in a photopolymerization process powered 79 
by free oxygen radicals introducing additional cross-links within and between collagen fibers 80 
in the corneal stroma up to a depth of 300µm.(13) The result is an increase in the 81 
biomechanical and biochemical stability of the cornea and reactive oxygen species (ROS)-82 
induced damage to cells and microorganisms in the irradiated area.(14-18) In a riboflavin-83 
saturated cornea of ≥ 400µm thick, the UV-A irradiance generated at the level of the 84 
endothelium with the standard CXL procedure is less than half the endothelial damage 85 
threshold. All structures behind a 400µm thick corneal stroma, including the corneal 86 
endothelium, iris, lens epithelium and retina are exposed to a residual UV radiation exposure 87 
that is regarded as safe for these structures.(13)  88 
Several groups have demonstrated the antimicrobial effect of CXL against a host of bacterial 89 
isolates in vitro.(19-21) 90 
CXL was developed to increase the stability and reduce the biodegradation of the corneal 91 
collagen matrix in primary and secondary corneal ectatic diseases, most notably 92 
keratoconus.(22) However, the properties of CXL-induced increased corneal rigidity, 93 
decreased susceptibility to collagenase enzymes and ROS-induced toxicity to microorganisms 94 
make CXL an attractive adjunctive therapy for the treatment of melting keratitis.  95 
During the last five years several groups have published studies in humans where CXL was 96 
used as an adjuvant treatment in cases where medical therapy had failed to control infectious 97 
melting keratitis. In all single cases and small case studies published, CXL led to an arrest of 98 
progression of infectious melting.(23-27) In two larger case series with 16 and 40 enrolled 99 
patients the reported success rates were 100 and 85%, respectively.(28, 29) In one of these 100 
two case series CXL was succesfully used as sole treatment, without the use of antibiotics, to 101 
stabilize corneas with confirmed (13 of 16 cases) and presumed (3 of 16 cases) bacterial 102 
keratitis.(28)  103 
The use of CXL as an adjunctive therapy for the treatment of melting keratitis may become its 104 
major indication in veterinary medicine. We have recently published a pilot study describing 105 
the successful use of CXL to treat melting keratitis in three dogs and three cats. Superficial 106 
corneal pigmentation, sequestrum formation and bullous keratopathy were observed during 107 
follow-up. It was unclear whether these pathologies were preexisting conditions or 108 
complications of the CXL treatment and/or the initial melting keratitis.(30) Hellander-Edman 109 
et al. have described the successful stabilization via CXL of eight out of nine equine corneas 110 
with melting keratitis.(31)  111 
Antimicrobial drug resistance of pathogens seems to be an increasing problem in veterinary 112 
ophthalmology.(32, 33) The treatment of certain drug resistant microorganisms may be 113 
facilitated by the direct antimicrobial effect of CXL.(19)  114 
As far as the authors know, no controlled clinical studies attempting to compare the efficacy 115 
of CXL to that of medical treatment for melting keratitis have been undertaken. 116 
Therefore, the objectives of this study were to (i) assess the effectivity of CXL treatment in 117 
stabilizing the cornea of dogs and cats with melting keratitis and (ii) to compare the 118 
effectivity and complication rate of CXL to those of an intensive standard medical treatment 119 
protocol. 120 
 121 
 122 
Materials and methods 123 
Trial design 124 
A pProspective interventional, non-randomized, controlled study was designed to assess 125 
whether CXL treatment of eyes suffering from melting keratitis can decrease the incidence of 126 
surgical salvage procedures necessary to stabilize the cornea and of surgical globe removal. 127 
The purpose of the study was to test the null-hypothesis stating that no difference in outcome 128 
exists between the patient group undergoing CXL + medical treatment compared to the 129 
control group of patients receiving medical therapy alone.  130 
Animals 131 
Forty-nine eyes (46 animals) with corneal melting were included in this interventional 132 
prospective study between October 2009 and October 2012. The entry criteria for inclusion 133 
into the study were: (i) species (dog or cat), (ii) clinical diagnosis of keratomalacia/melting 134 
keratitis (see pretreatment examination), (iii) complete ophthalmic examination by a board 135 
certified ophthalmologist (BS, SP) or an A/ECVO ophthalmology resident (NG, FM, KV) at 136 
initial presentation and all subsequent rechecks, (iv) willingness and ability of the owner to 137 
comply with the intensive topical treatment schedule and to return for follow up 138 
examinations. The presence of a corneal perforation or descemetocele or the complete 139 
absence of any normal appearing corneal stroma in the ulcer site led to exclusion from the 140 
study.  141 
Pretreatment examination 142 
Pretreatment analysis included slit-lamp examination, fluorescein staining, measurement of 143 
ulcer size using calipers, photography, cytology and corneal culture and sensitivity testing. 144 
Cytology samples were collected from all animals apart from two dogs in the control group, 145 
and two dogs and two cats in the CXL-treated group. Culture and sensitivity samples were 146 
collected from all cats and all dogs, apart from one dog in the CXL-treated group. The 147 
diagnosis of corneal melting was based on a subjective evaluation of stromal stability/melting 148 
activity, including the presence of cellular infiltrates, the perceived stability of the stroma, the 149 
presence of changes in corneal contour and ulcer depth and the presence of malacic corneal 150 
material in the ulcer area.  151 
Experimental groups:  152 
All patients were treated according to the same standard medical treatment protocol, including 153 
the use of topical antibiotics, topical and systemic collagenase inhibitors and, if needed, 154 
topical atropine 1% and systemic meloxicam and buprenorphine. Table 1 summarizes the 155 
medical treatment protocol. The patients were divided into two groups depending on whether 156 
the cornea was CXL-treated or not. Patients in the control group were client owned animals 157 
meeting the entry criteria that were treated with medical treatment alone. Thirty eyes (27 158 
animals, 23 dogs and 4 cats) were enrolled in the control group. Patients in the CXL group 159 
were client owned animals meeting the entry criteria that were treated with medical treatment 160 
and CXL. Nineteen eyes (19 animals, 12 dogs and 7 cats) were enrolled in the CXL group. 161 
Discontinuation of medical treatment was judged unethical in light of the unknown efficacy 162 
of CXL treatment in dogs and cats. Allocation to treatment groups was not performed 163 
randomly and depended on owner and clinician preference. Table 2 demonstrates the 164 
composition of the study groups.  165 
The CXL procedure 166 
CXL was performed as previously described.(30) Briefly, all procedures were performed 167 
under general anesthesia with the eye anesthetized topically and positioned in a horizontal 168 
plane (Fig. 1). Isoosmolar 0.1% riboflavin drops (freshly mixed 0.5% aqueous riboflavin 169 
(Vitamin B2; Streuli, Uznach, Switzerland) and sterile 20% dextran T-500 solutions) were 170 
administered to the cornea every 3 minutes for 30 minutes. The corneas were then irradiated 171 
for 30 minutes with a 365 nm wavelength ultraviolet A light (irradiance: 3 mW/cm2, UV-X; 172 
Peschke Meditrade, Cham, Switzerland) focused on the corneal surface, while taking care to 173 
avoid the corneal limbus.(34, 35) Riboflavin solution was applied to the cornea every 3 174 
minutes during the irradiation period. CXL was performed in the presence of a certain risk of 175 
UV-induced cytotoxicity to the endothelium in corneas demonstrating significant loss of 176 
corneal stroma. 177 
Posttreatment follow-up 178 
The median available follow-up was 2 (range 0.1 to 12) months and 3 (range 0.25 to 22.5) 179 
months in the control and CXL groups, respectively. Follow up included slit-lamp 180 
examination, fluorescein staining, ulcer size measurements with calipers, photographic 181 
documentation and documentation of complications during all reexaminations.  182 
Posttreatment examinations were performed during initial hospitalization, at days 7, 14 and 183 
28 after initiation of treatment and at various timepoints during the long-term follow-up. The 184 
primary endpoint variable to be measured was the occurrence of (or need for) surgical 185 
stabilization or removal of the eye, which was interpreted as treatment failure. Surgical 186 
intervention was recommended in cases where a significant portion of the residual corneal 187 
stromal thickness was lost due to progressive corneal melting during follow up. Surgical 188 
intervention was typically recommended if an additional amount of stroma greater than 20% 189 
of the normal thickness of the cornea was lost during follow up. For eyes in the control group, 190 
CXL was offered as ‘surgical’ stabilization option. The time interval between treatment 191 
initiation and the stabilization of the corneal stroma (as determined by the lack of signs of 192 
melting, see pretreatment examination), the time interval between treatment initiation and 193 
closure of the corneal defect (defect fluorescein negative) and the registration and 194 
documentation of complications were secondary endpoint variables.   195 
Statistical evaluation 196 
Treatment failure/success, gender and laterality were evaluated using Fisher’s exact test for 197 
contingency tables. The data for dogs and cats were evaluated separately. Differences 198 
between control and CXL groups regarding age, ulcer depth, ulcer size, interval treatment 199 
start to stroma stabilization, interval treatment start to defect closure, stromal thinning at last 200 
visit and length of follow up were evaluated using the Wilcoxon rank sum (Mann-Whitney U) 201 
test for unpaired non-parametric data. Differences within groups in ulcer depth at 202 
presentation, ulcer depth prior to CXL and maximal ulcer depth observed during the study 203 
period were evaluated using the Wilcoxon signed rank test for paired non-parametric data. 204 
The level for statistical significance was set at p < 0.05 for all comparisons. GraphPad Prism 205 
version 6.00 for Windows (GraphPad Software, La Jolla CA, USA, www.graphpad.com) was 206 
used for all statistical analyses.  207 
 208 
 209 
Results 210 
Treatment groups 211 
The number of patients was unequally distributed across treatment groups. Baseline 212 
characteristics were well balanced between the canine control and CXL groups with the 213 
possible exception of low tear production (< 15 mm/min) measured at presentation (Table 2). 214 
Brachycephalic animals were equally distributed over and overrepresented in the canine 215 
control and CXL groups.  216 
The median age of the cats enrolled in the study was 11.5 years for the control group and 10 217 
years for the CXL group. The median age of the dogs in these groups was 3.8 and 3 years, 218 
respectively. No significant age difference was found between the control and CXL groups. 219 
The right eye was affected more often in cats and more male cats than female cats were 220 
enrolled in the study. All cats in the control group were brachycephalic, whereas only 2/7 cats 221 
in the CXL group were brachycephalic.  222 
Clinical features 223 
The numbers of patients with the primary end point (treatment failure/eyes treated) by group, 224 
secondary end points, culture results and complications over a median follow-up of 1.5-5 225 
months are demonstrated in Table 3.  226 
Inflammatory cellular infiltrates were present in all affected corneas and slit-lamp 227 
examination showed loss of corneal stroma in all cases. Significant progression of corneal 228 
melting was observed in 9/30 eyes (30%)  in the combined canine and feline control groups 229 
and 5/19 eyes (26%) in the combined CXL groups. Surgical stabilization was recommended 230 
for these eyes and this was interpreted as failure of the allocated treatment. The median time 231 
from treatment start to failure was 2 days in the control group (range 1-24 days) with only 2 232 
of 9 eyes failing treatment after one week of follow-up. Median treatment start to failure time 233 
in the CXL group was 6 days (range 1-18 days). One eye in the feline control group failed 234 
treatment, all other eyes failing treatment were canine eyes. The number of eyes that failed 235 
treatment was not significantly different when comparing CXL treated eyes to eyes that 236 
received medical treatment alone in either dogs (p=0.71), cats (p=0.36) or dogs and cats 237 
combined (p=1).  238 
A conjunctival pedicle flap was used to stabilize one cornea failing treatment in the control 239 
group. Conjunctival pedicle flap placement was strongly recommended for a second control 240 
group patient but declined by the owner. Seven eyes of 6 control group animals were 241 
succesfully treated with CXL as rescue therapy.  242 
Four of the five corneas failing treatment in the CXL group were stabilized using a 243 
conjunctival pedicle flap. A nictitating membrane flap was used in the fifth eye to protect a 244 
descemetocele during second intention healing. All surgically treated eyes that failed initial 245 
treatment were stabilized and retained some form of vision.  246 
One patient with a suspected systemic immunodeficiency was enrolled in the CXL group and 247 
failed treatment. Two out of three patients with poorly controlled diabetes mellitus which 248 
were enrolled in the control group  failed treatment. One of these two patients presented in a 249 
ketoacidotic crisis with bilateral melting keratitis and the second patient was suspected of 250 
having Ccushing’s disease.    251 
The ulcer area size was much larger in the CXL group than in the control group in both cats 252 
(not significant) and dogs (p=0.01). The ulcer area size was much larger in the cats than in the 253 
dogs in both groups. At presentation, the ulcers of patients in the CXL group were deeper 254 
than in the control group in dogs (p=0.04) but not in cats. The interval from treatment start to 255 
stabilization of the corneal stroma and the interval from treatment start to closure of the 256 
epithelium over the defect were longer in the CXL group compared to the control group in 257 
dogs (p=0.03 and 0.02, respectively) and cats (not significant). There were no significant 258 
differences in the length of follow up between groups. The maximal ulcer depth observed 259 
during follow-up was not significantly different between the control and CXL groups. A 260 
significant increase in ulcer depth was observed in both groups in dogs when comparing the 261 
ulcer depth at presentation to the maximal ulcer depth observed during follow-up. Ulcer depth 262 
increased from a median of 35% to 50% stromal loss in the control group (p=0.001) and from 263 
50%  to 55% stromal loss in the CXL group (p=0.03). The differences were not significant in 264 
cats. Stromal thinning at the site of the previous ulcer, estimated at the last recorded visit, was 265 
more pronounced in the control group (20%) compared to the CXL group (2.5%) in dogs 266 
(p=0.03). No difference was observed in cats.  267 
Culture and cytology 268 
One of 11 cat eyes were positive on cytology, compared to 10/38 dog eyes. All cytology 269 
positive eyes also yielded positive culture results in both dogs and cats. In dogs, 18/26 (69%) 270 
cultures were positive in the control group, compared to 5/11 (45.5%) cultures in the CXL 271 
group. One eye in the CXL group had no culture submitted. In cats, 2/4 cultures were positive 272 
in the control group, compared to 4/7 cultures in the CXL group. Twenty-five of a total of 34 273 
bacterial isolates were cocci of the genus Staphylococcus or Streptococcus.  274 
Complications 275 
A certain amount of fibrosis was present at the location of the initial ulcer in all eyes, 276 
regardless of the treatment group. The density of the fibrosis varied from mild fibrosis which 277 
was not obvious to the naked eye, but easily detectable with the use of a slitlamp 278 
biomicroscope at a 10x magnification, to complete opacification of the cornea. The area size 279 
affected depended on the area size of the initial ulcer. Appearance of corneal pigmentation (4 280 
eyes) or progression of previously existing corneal pigmentation (7 eyes) was observed in 281 
11/26 eyes (42%) in the canine control group. Eight of these eyes belonged to brachycephalic 282 
dogs, and seven to Pugs. Appearance of corneal pigmentation (1 eye) or progression of 283 
previously existing corneal pigmentation (3 eyes) was observed in 4/12 eyes (33%) in the 284 
canine CXL group. Two of these eyes belonged to brachycephalic dogs, both Pugs.  285 
Dense corneal edema with subepithelial and intrastromal bullae was observed in one dog in 286 
the control group and in one dog in the CXL group. Corneal bullae had been observed during 287 
wound healing in the cornea of the control group patient. At three weeks after treatment start 288 
the cornea was stable and fluorescein negative and focal edema, neovascularization and 289 
fibrosis were visible. Significant superficial pigmentation, fibrosis and residual microcystic 290 
edema were observed in the cornea from the patient treated with CXL at last recheck at 7.5 291 
months after treatment start. 292 
One out of four cats in the control group (persian) developed a sequestrum two weeks after 293 
the start of treatment and 2/7 cats in the CXL group developed a corneal sequestrum during 294 
the corneal healing process. The first cat (ESH) developed a sequestrum two weeks after CXL 295 
and this sequestrum was spontaneously extruded three weeks later. The second cat (Persian) 296 
developed a faint brown staining in the superficial stroma at the ulcer site two months after 297 
CXL. This suspected sequestrum had disappeared at recheck two months later. This cat later 298 
developed a corneal erosion and similar transient brown staining in the stroma of the fellow 299 
eye. 300 
Deviations and violations of protocol  301 
(i) Surgical intervention, constituting treatment failure, was recommended if a loss of more 302 
than 20% of the corneal stroma was observed in addition to the stromal loss at presentation. In 303 
some cases an exception was made to that rule. One eye demonstrating a progression from 304 
70% to 80% stromal loss failed treatment in the CXL group. Surgical intervention was 305 
recommended for this patient because of a significant increase in ulcer area size and the 306 
presence of an instable looking, heavily infiltrated ulcer bed. One eye that was counted as a 307 
treatment success in the CXL group demonstrated ulcer depth progression from 50% to 75% 308 
stromal loss before the rest of the stroma was diagnosed as being stable. Due to a massive 309 
inflammatory cell infiltration affecting the superficial stroma of the entire cornea at 310 
presentation, the examiners were not certain whether the ulcer deepening was a result of 311 
progressive melting or merely of sloughing of the cellular infiltrates.  312 
Four eyes with a stromal loss progression ≤ 20% were counted as treatment failures in the 313 
control group. One eye did not demonstrate ulcer deepening, but the appearance of additional 314 
stromal ulcers despite medical therapy instead. Two eyes with an additional stromal loss of 10 315 
and 15%, respectively, demonstrated ulcer deepening and a sudden protrusion of central ulcer 316 
bed stroma within one day. One eye demonstrated an additional loss of 20% of stroma, 317 
significant inflammatory cell infiltration of the ulcer bed, the persistent presence of coccoid 318 
bacteria on repeated cytology samples and the appearance of a  lipid flare.  319 
(ii) Serum treatment was discontinued shortly after CXL in one cat due to patient compliance 320 
problems and concerns regarding the sterility of the dropper bottle nozzle. One dog in the 321 
CXL group did not receive topical serum, nor systemic doxycycline treatment. One dog in the 322 
CXL group received topical chloramphenicol treatment in addition to the medical protocol. 323 
CXL treatment was successful in these three patients.   324 
CXL rescue therapy 325 
Seven eyes of 6 animals that failed medical therapy were succesfully treated with CXL as 326 
rescue therapy. Significant ulcer deepening from 30% (median) stromal loss at first 327 
presentation to 60% (median) immediately prior to CXL (p=0.03) had been observed. These 328 
patients were censored and the follow up data presented in table 4 was not used for the study. 329 
Interestingly, ulcer depth did not significantly progress after CXL (Fig. 2 b-e) and all seven 330 
corneas were stabilized. Follow-up time and the time intervals between CXL and stabilization 331 
of the stroma and defect closure were similar to those of the patients in the CXL study group. 332 
One cat (Persian) underwent CXL after 1 wk of medical Tx and developed a sequestrum 2 333 
wks after CXL. 334 
 335 
 336 
Discussion 337 
The study results are difficult to interpret due to two major limitations of this study.  338 
(i) The group size is too small to give the study the statistical power that it needs to identify a 339 
potential true difference in treatment efficacy between the groups.  340 
Especially the low number of enrolled cats was a likely reason for non significance of all 341 
statistical comparisons between the feline control and CXL groups. The decision to stop the 342 
current non randomized trial was made based on a statistical evaluation of the study results at 343 
this time. A study with a patient population five times the size of the present study and an 344 
identical distribution of patient characteristics and clinical results  between groups would still 345 
yield a statistically non-significant difference between the control and CXL groups. Such a 346 
study would take 10 years to complete with the current speed of patient enrollment. 347 
(ii) Selection bias likely played an important role in this study since the distribution of 348 
patients between the control and CXL groups was not randomized and not uniform.(36) The 349 
patients in the canine CXL group had significantly deeper and larger ulcers at initial 350 
presentation compared to those in the control group. This may be the reason for the 351 
significantly longer interval from treatment start to stroma stabilization and from treatment 352 
start to defect closure in the CXL group compared to the control group in dogs. This 353 
conclusion is supported by the results from Price et al. who have reported a correlation 354 
between infiltrate diameter and area size at presentation and time to infiltrate resolution, with 355 
smaller infiltrates clearing up much faster than larger infiltrates.(29) 356 
The fact that patient evaluation prior to and after treatment was performed in an unmasked 357 
manner is another limitation of this study with an unknown effect on the outcome.  358 
Some of the results from this study suggest that CXL could be a useful adjunctive therapy for 359 
the treatment of corneal melting in veterinary patients.  360 
(i) The number of eyes that failed treatment was not significantly different when comparing 361 
CXL treated eyes to eyes that received medical treatment alone, despite the poorer situation 362 
for the CXL patients at initial presentation. (ii) Ulcer deepening during follow up was more 363 
pronounced in the canine control group (from 35% to 50% stromal loss) compared to the 364 
canine CXL group (from 50%  to 55% stromal loss), although ulcer deepening was 365 
statistically significant in both groups. (iii) Seven of the nine eyes that failed medical 366 
treatment were successfully stabilized with CXL. 367 
The overall stabilization rate after CXL of 74% in this study was lower than the success rates 368 
of 100 and 85% in previous case series of human patients by Makdoumi et al. and Price et al., 369 
respectively(28, 29), and lower than the success rate of 89% in a small equine case series 370 
described by Hellander-Edman et al.(31) Treatment success was defined as ulcer healing by 371 
Makdoumi et al. However, an amniotic membrane graft was used after CXL treatment in one 372 
patient to reach this goal. Surgical intervention was interpreted as treatment failure in our 373 
study and in the studies by Price et al. and Hellander-Edman et al.  374 
The lower success rate observed in our study may also be explained by the advanced disease 375 
state at presentation of most of the ulcers in the CXL group in our study: stromal loss ≥ 50% 376 
in 16/19 ulcers, ulcer diameter range 2.3-13.4 mm (median 6.2 mm). The size of the ulcers 377 
ranged between 0.1 and 2.5 mm in diameter (median 1.0 mm) in the study by Makdoumi et 378 
al.(28) and 0.5 and 12 mm in diameter (median 3.0 mm) in the study by Price et al.(29)  379 
Infiltrate depth was not a measured data point in either study. However, Price et al observed 380 
that infiltrate depth generally increased with increasing infiltrate area. They also noted that 381 
after CXL treatment the disease process resurged within several days after initial stabilization 382 
in some cases where infiltrates reached deeper than 50% of the corneal thickness.(29). The 383 
same observation was made by Makdoumi et al. in one patient with a deep stromal 384 
keratitis.(28) They theorized that a corneal infiltrate situated deeper than 300 µm from the 385 
corneal surface might well be shielded from the effects of CXL. Whether ulcer depth of more 386 
than 50% stromal loss at presentation could be a negative prognostic indicator for CXL 387 
treatment is only partially supported by our results. Three of 4 ulcers that initially presented 388 
with > 50% stromal loss failed treatment in the canine CXL group, compared to 0/3 in the 389 
feline CXL group. Treatment failures in these dogs may be related to a lack of normal 390 
crosslinkable stroma in these ulcers. Ulcer depth and area size were not reported for the 391 
equine patients of Hellander-Edman et al.(31) 392 
Three out of four patients with a recognized systemic illness failed treatment in this study, 393 
one of which failed medical treatment, but was stabilized with CXL rescue treatment. Patients 394 
with systemic abnormalities, like diabetes mellitus, ketoacidosis and Cushing’s disease, that 395 
have a negative influence on immunocompetence and/or wound healing may have a poorer 396 
prognosis regarding corneal ulcer healing compared to systemically healthy patients.(37, 38)  397 
The ulcers were larger in the cats and the cats were older compared to the dogs in both groups 398 
in this study. We have no explanation for these differences. Only one of 11 cats (9%) failed 399 
treatment compared to 13/38 dogs (38%). The cause for and significance of this difference is 400 
unclear but could be related to the different underlying primary causes for melting keratitis in 401 
dogs and cats. A brachycephalic facial conformation likely played an important ulcer 402 
permissive role in our canine and possibly feline patients.(3, 4), whereas Herpesvirus keratitis 403 
has also been implicated in cats.(39) 404 
Forty-six to 69% of the submitted culture samples yielded positive test results in this study 405 
and 74% of the culture isolates were cocci of the genus Staphylococcus (45%) or 406 
Streptococcus (29%), which is in agreement with previous studies in dogs.(40-42) 407 
Literature descriptions of a lower prevalence of conjunctival and corneal surface bacterial 408 
flora in cats compared to other species (41, 43) could not be confirmed in the present study. 409 
Eyes with negative corneal cultures were included in the trial, as would be the case in clinical 410 
practice. The culture results did not seem to influence or predict the treatment outcome. Six of 411 
9 cases failing treatment in the control group were culture positive compared to 20 positive 412 
cultures out of a total of 30 cultures submitted in that group. Three out of 5 cases failing 413 
treatment in the CXL group were culture positive compared to 9 positive cultures out of a 414 
total of 18 cultures submitted in the CXL group.  415 
Three cases of MRSA/I were identified. One MRSA positive ulcer of a cat treated with CXL 416 
was stable 4 days after treatment. The MRSA was sensitive to oxytetracycline and 417 
doxycycline however. Two dogs that both failed medical treatment were MRSA/I positive. 418 
Both ulcers were treated with CXL as rescue treatment and both corneas were stabilized. 419 
However, based on the antibacterial sensitivity test results, topical Chloramphenicol treatment 420 
for which these MRSA/I were sensitive had been initiated between CXL treatment and 421 
stabilization of the stroma in both cases. Therefore, the stabilization of the ulcers in these two 422 
eyes can not unequivocally be contributed to the CXL effect alone since the change in 423 
antibiotic treatment might have had a significant impact as well.  424 
Direct CXL treatment related complications have not been observed in this study.  425 
The incidence of progressive pigmentary keratitis after treatment was similar in both groups 426 
of dogs. Pre-existing corneal pigmentation was present in 13/26 eyes in the control group and 427 
in 5/12 eyes in the CXL group in dogs, ≥ 80% of which were brachycephalics and ≥ 60% of 428 
which were Pugs in both groups. Most of the dogs that demonstrated post-treatment 429 
appearance or progression of pigmentary keratitis in both groups were also brachycephalics 430 
and Pugs. These numbers are not surprising since chronic keratitis caused by medial canthal 431 
trichiasis, lower nasal eyelid entropion or macropalpebral fissure(44) is a known stimulus for 432 
the development of corneal pigmentation and can also be a predisposing factor for the 433 
development of melting keratitis, especially in brachycephalic breeds.(3) Eight of nine Pugs 434 
in the control group and 3/4 in the CXL group presented with preexisting pigmentary 435 
keratitis, which progressed in 7/8 and 2/3 of these dogs, respectively. These numbers 436 
correspond to a recent report by Labelle et al. who reported pigmentary keratitis in 80.3% of 437 
295 pugs examined in a large prospective study.(45) 438 
The incidence of post-treatment endothelial decompensation was low in both groups of dogs 439 
(one dog in each group). The CXL procedure itself might have led to the endothelial damage 440 
in the CXL-treated patient, since the observed pretreatment stromal loss was significant at 441 
60% in this patient. CXL can pose a serious hazard to the endothelium if an insufficiently 442 
thick, riboflavin saturated stromal layer is shielding the endothelium from hazardous levels of 443 
UVA energy.(46) However, more dogs with ulcers of similar depth were treated with CXL in 444 
this study and none developed similar symptoms. Melting keratitis is one of the many other 445 
potential causes for endothelial decompensation.(3) 446 
The incidence of sequestrum formation was similar in both groups of cats and could be 447 
associated with CXL and keratomalacia related keratocyte apoptosis.(47) 448 
This seems to be in agreement with the current literature. No specific safety reports have been 449 
published on CXL yet. However, a very low rate or absense of significant, sight threatening 450 
complications has been reported in clinical trials registered to gain FDA approval for the use 451 
of CXL in humans.(22, 48-52) 452 
 453 
A prospective interventional, randomized, controlled study accepting only dogs has been 454 
started in our clinic to evaluate the effectivity of CXL + medical treatment compared to 455 
medical therapy alone. Power calculations based on published results from human(28, 29) and 456 
equine(31) case studies and the results of the trial described in this manuscript predict a 457 
timeframe of at least three to five years for this randomized trial to be completed. The authors 458 
therefore felt that publication of the results of the present study, especially regarding the lack 459 
of observed CXL-related complications would benefit the veterinary ophthalmic community.  460 
Based on the similar failure rates in the control and CXL treatment groups despite the poorer 461 
situation in the CXL group at initial presentation, the tendency for the ulcers in the CXL 462 
group to show less deepening and the stabilization of all corneas that received CXL rescue 463 
treatment, the authors believe that CXL has its place as an adjunctive therapy for the 464 
treatment of melting keratitis in veterinary ophthalmology.  465 
 466 
 467 
Figures 468 
TABLE 1. Study protocol medical treatment melting keratitis 469 
TABLE 2. Baseline characteristics of the patients 470 
TABLE 3. Clinical results and follow up 471 
TABLE 4. CXL as rescue treatment in patients failing medical treatment 472 
FIGURE 1. Clinical setup of the CXL procedure under general anesthesia.  473 
The irradiation source is placed at a distance of approximately 5 cm to the eye (a). The cornea 474 
is positioned in a horizontal plane and yellow colored riboflavin drops are applied (b). The 475 
green riboflavin fluorescence is apparent during irradiation at 365 nm (c). The application of 476 
fluorescein dye shortly before CXL is probably best avoided due to UV-irradiation absoption 477 
spectrum overlap of fluorescein and riboflavin.  478 
FIGURE 2. Photographs of the ocular adnexa and cornea of a dog before and after 479 
undergoing rescue CXL-treatment. 480 
A two-year-old French Bulldog was treated medically according to study protocol (Table 1) 481 
for a melting ulcer OD. After one week of treatment the corneal stroma was still judged to be 482 
instable and 30% of the stroma had been lost at the deepest point of the ulcer (a). During the 483 
following two weeks no significant changes were observed despite continued treatment. A 484 
sudden rapid deterioration occurred after three weeks of treatment and the dog was presented 485 
with a deep, actively melting ulcer. At the deepest point of the ulcer 60 % of the stroma had 486 
been lost (b). CXL was performed as rescue therapy and the patient was removed from the 487 
study control group. One week after CXL the ulcer had not deepened further, the ulcer edges 488 
were epithelializing and granulation tissue was invading the ulcer bed. Inflammatory cell 489 
infiltrates were still present in the central to superotemporal ulcer bed (c). Two weeks after 490 
CXL the ulcer bed was free of inflammatory cell infiltrates and the ulcer was fluorescein 491 
negative. No further ulcer deepening had been observed (d). One month after CXL the defect 492 
was filled with granulation tissue and the cornea peripheral to the lesion was clearing (e).        493 
 494 
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